Patent · US Active

Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen

US12384847B2 · kind B2 · utility

0Cited by

66References

20Claims

0Family size

Assignee

Dragonfly Therapeutics, Inc. · US

Inventors

Gregory P. Chang · Medford, US
Ann F. Cheung · Lincoln, US
Asya Grinberg · Lexington, US
Eva Gutierrez · Illertissen, DE
William Haney · Wayland, US
Nicolai Wagtmann · Concord, US
Bradley M. Lunde · Lebanon, US
Bianka Prinz · Lebanon, US

Key dates

Filing date	Feb 8, 2019
Grant date	Aug 12, 2025
Priority date	—
Expiry date	Sep 20, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.